Wilson, et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol. 2014 Mar;34(6):1136-44. doi: 10.1128/MCB.01372-13. Epub 2014 Jan 13. PMCID: PMC3958034
Helming, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014 Mar;20(3):251-4. doi: 10.1038/nm.3480. Epub 2014 Feb 23. PMCID: PMC3954704
Shao DD, et al. ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res. 2013 Apr;23(4):665-78.
Rosenbluh J, et al. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151(7):1457-73. PMCID: PMC3530160.
Ren Y, et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med. 2012 Aug 15;4(147):147ra112.
Luo B, et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20380-5. PMCID: PMC2629277.
The Cancer Cell Line Encyclopedia provides public access to genomic data, analysis and visualization for about 1000 cell lines.
The Cancer Therapeutics Response Portal enables analyses a genomic cancer cell-line profiling to identify more comprehensively relationships between genetic and lineage features of human cancer cell lines and small-molecule sensitivity.
CTD2 bridges the gap between the enormous volumes of data generated by genomic characterization studies and the ability to use these data for the development of human cancer therapeutics. It specializes in computational and functional genomics approaches critical for translating next-generation sequencing data.